T2 BIOSYSTEMS, INC. (NASDAQ:TTOO) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders.

(a) The Annual Meeting of Stockholders of T2 Biosystems, Inc. (the “Company”) occurred on June8, 2018.

(b) There were a total of 36,019,883 shares of the Company’s common stock, par value $0.001 per share, outstanding and entitled to vote at the Annual Meeting. At the Annual Meeting, 19,573,242 shares of common stock were presented in person or by proxy, which represented 54.34% of the shares entitled to vote; therefore, a quorum was present. The following proposals were submitted by the Board of Directors to a vote of the stockholders, each of which was approved by the requisite vote. The votes with respect to each proposal are set forth below.

to the foregoing votes, the ClassI Director nominees listed above were elected to serve on the Company’s Board of Directors until the Company’s 2021 Annual Meeting of Stockholders.

About T2 BIOSYSTEMS, INC. (NASDAQ:TTOO)

T2 Biosystems, Inc. is an in vitro diagnostics company engaged in developing a technology platform offering an alternative to diagnostic methodologies. The Company’s T2 Magnetic Resonance platform (T2MR) enables detection of pathogens, biomarkers and other abnormalities in a range of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as one colony forming unit per milliliter (CFU/mL). The Company’s initial development efforts target sepsis, hemostasis and Lyme disease. T2MR is a miniaturized, magnetic resonance-based approach that measures how water molecules react in the presence of magnetic fields. Its platform detects a range of targets, including molecular targets, such as deoxyribonucleic acid (DNA), immunodiagnostics, such as proteins, and a range of hemostasis measurements. The Company offers T2Dx Instrument (T2Dx) and the T2Candida Panel.